drugset / Trial / NCT05049057
Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI
Phase 2
Recruiting
404 enrolled
Henry M. Jackson Foundation for the Advancement of Military Medicine
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study aims to assess the effect and safety of erenumab compared to placebo for the treatment of acute posttraumatic headache (PTH) in military service members and civilians with mild traumatic brain injury (mTBI).
Timeline
- Start
- 2022-07-19
- Primary completion
- 2026-05-19
- Completion
- 2027-05-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erenumab | Monoclonal antibody | 140 mg | Subcutaneous |